One protein, two heart diseases: could atrial fibrillation and heart failure share the same root cause?
For decades, atrial fibrillation and heart failure have been treated as entirely separate diseases.
The protein in question is TBX5, a transcription factor — essentially a master switch that controls which genes are turned on or off in heart cells. When TBX5 expression declines, the heart can fail in two distinct ways: the upper chambers may begin beating erratically, or the heart’s pumping function may gradually deteriorate. Which outcome occurs likely depends on additional genetic and environmental factors — but according to this research, the underlying trigger may be identical in both cases.
That might sound like a technical nuance, but the implications are significant. Together, atrial fibrillation and heart failure affect hundreds of millions of people worldwide, and their current treatments are completely different. Atrial fibrillation is managed with anticoagulants, rhythm-control medications, or ablation — deliberately damaging small areas of heart tissue to interrupt faulty electrical signals. Heart failure is treated with ACE inhibitors, beta-blockers, and diuretics. If both conditions share the same molecular origin, a therapy targeting TBX5 could potentially address both at once.
The problem with targeting transcription factors
TBX5 regulates a large number of downstream genes, making it a central hub in cardiac cell biology — but also a notoriously difficult drug target. Most medications work by binding to a specific receptor or enzyme with a well-defined binding site. Transcription factors typically lack that kind of accessible structure, which is why they have historically resisted pharmacological intervention. So the question isn’t just whether TBX5 is the shared cause, but whether that knowledge can be translated into a workable treatment.
Researchers note that declining TBX5 expression may itself be a consequence of aging — it is well established that gene expression in cardiac cells shifts as people grow older. This situates the findings within a broader framework of age-related organ decline, and raises the possibility that both conditions are, in part, manifestations of biological aging rather than purely separate diseases.
Two diagnoses, one disease?
The researchers are not calling for the two conditions to be merged diagnostically, but they are arguing for a rethink of treatment strategy. If the underlying pathology is shared, it may make more sense to intervene upstream — earlier in the biological cascade — rather than continuing to manage each condition’s symptoms in isolation. Whether that is achievable depends on future research into how TBX5 expression is regulated and whether it can be restored once it has declined. For now, that remains unanswered.